Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ArkBio

ArkBio?uq=UG6efJS6
2014 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
5 INVESTORS
Description

Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection and viral hepatitis. The company's leading drug AK0529 specifically inhibits RSV (Respiratory Syncytial Virus) replication by blocking viral entry and syncytial formation, providing an effective first-line antiviral therapy for RSV infection in infants and the elderly.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Room 701, 780 Cailun Road
  • Pudong New Area
  • Shanghai, 201203
  • China

+86 021 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ArkBio’s full profile, request a free trial.

ArkBio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 06-Feb-2017 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 08-Apr-2015 Completed Clinical Trials - Phase 1
1. Early Stage VC Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

ArkBio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bioventure Investment Venture Capital Minority 000 0000 000000 0
Oriza Ventures Venture Capital Minority 000 0000 000000 0
Morningside Group PE/Buyout Minority 000 0000 000000 0
Qiming Venture Partners Venture Capital Minority 000 0000 000000 0
TF Capital Venture Capital Minority 000 0000 000000 0

ArkBio Executive Team (3)

Name Title Board
Seat
Contact
Info
Jim Wu Ph.D Chief Executive Officer & Founder
Stephen Toovey Ph.D Chief Medical Officer
Gianni Gromo Ph.D Scientific Advisor